FAPI imaging in non-small cell lung cancer treated before surgery
Tests FAPI-PET/CT and fluorescence imaging in adults with non-small cell lung cancer.
Key facts
- Who runs it
- Peking University People's Hospital
- Where
- Beijing, ChinaSee the site
- Trial code
- Registry title
- FAP-targeted PET/NIR in Lung Malignant Tumors
- Status
- Recruiting
- People taking part
- 200 people, planned
- Started
- 3 Jun 2025
- Expected to end
- 31 Dec 2027
- Type of study
- Observational
- Treatments tested
- PET/CT scans
- Record updated
- 1 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 70 with lung cancer confirmed by biopsy who are having treatment before surgery. They will have a special PET scan and fluorescence imaging.
- Age
- 18 to 70 years
- Sex
- Women and men can both join.
- Disease stage
- Stage II-IIIB lung cancer (non-small cell) that can be removed by surgery.
- Earlier treatment
- Must have had standard treatment before surgery (chemotherapy, immunotherapy, or both) for at least 3 cycles. Must not have had other anti-tumor treatments.
Main reasons for not taking part
- Other cancers in the past or other anti-tumor treatments
- Not enough tumor tissue for testing and research
- Fewer than 3 cycles of treatment before surgery
- PET scan images of too low quality or missing
- Missing clinical and imaging data
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Age between 18 and 70 years old
- Have complete clinical and imaging data
- Prior to neoadjuvant therapy, the biopsy pathology showed lung cancer
- Able to retain sufficient tumor tissue for testing and research
- Sign informed consent
Who cannot take part
- Previously combined with other malignant tumors or received other anti-tumor treatments
- The duration of neoadjuvant therapy is less than 3 cycles
- Failure to collect sufficient tumor tissue for testing and research
- The dynamic scanning image quality of multimodal probe PET cannot meet the analysis standards or is missing
- Lack of clinical and imaging data
- There are situations where other researchers consider it inappropriate to participate in this study
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Where in China
- Peking University People's HospitalBeijing, ChinaContact: Kezhong Chen, MDTaking people
About the trial
What the trial wants to find out
Single center, prospective, diagnostic study. Patients with stage II-IIIB resectable NSCLC diagnosed by pathology were included. After receiving standard neoadjuvant therapy (chemotherapy/immunotherapy/combination therapy), FAPI-PET/CT and fluorescence imaging were performed one week before surgery. During the surgery, a near-infrared fluorescence navigation system was used to locate the tumor lesion. After surgery, the tumor bed range was determined by pathological gold standards (HE staining+immunohistochemistry), and the predictive efficacy and localization accuracy of FAPI-PET/fluorescence were compared and analyzed.
The group in the trial
- FAP-targeted PET in lung malignant tumors
Participant who conforms to the inclusion criteria will undergo 68Ga-FAPI/EB-FAPI PET/CT scans within 1 week.
Treatment: PET/CT scans
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Visualization Study on Tumor Progression Mechanisms and Key Molecular Functions in Neoadjuvant Immunotherapy for Lung Cancer: Preoperative Efficacy Prediction and Intraoperative Fluorescence Navigation
- Plain-language title
- FAPI imaging in non-small cell lung cancer treated before surgeryGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Fit questions
- Built from NCT07498933, who can take part
- Record updated
- 1 April 2026